Stephanie Hunt Walsh, MD in Glen Burnie, MD - Medicare Psychiatry

Stephanie Hunt Walsh, MD is a medicare enrolled "Psychiatry & Neurology - Psychiatry" physician in Glen Burnie, Maryland. She went to Texas Tech University Health Science Center School Of Medicine and graduated in 2001 and has 23 years of diverse experience with area of expertise as Psychiatry. She is a member of the group practice Kaiser Foundation Health Plan Of The Mid-atlantic States,inc and her current practice location is 301 Hospital Dr, Glen Burnie, Maryland. You can reach out to her office (for appointments etc.) via phone at (410) 787-4627.

Stephanie Hunt Walsh is licensed to practice in Maryland (license number D0064612) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1417072745.

Contact Information

	Stephanie Hunt Walsh, MD
	301 Hospital Dr, Glen Burnie, MD 21061-5803
	(410) 787-4627
	(410) 595-1994

Physician's Profile

Full Name	Stephanie Hunt Walsh
Gender	Female
Speciality	Psychiatry
Experience	23 Years
Location	301 Hospital Dr, Glen Burnie, Maryland
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Stephanie Hunt Walsh attended and graduated from Texas Tech University Health Science Center School Of Medicine in 2001

NPI Data:

NPI Number: 1417072745
Provider Enumeration Date: 03/19/2007
Last Update Date: 02/28/2022

Medicare PECOS Information:

PECOS PAC ID: 0244337103
Enrollment ID: I20070530000088

Medical Identifiers

Medical identifiers for Stephanie Hunt Walsh such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1417072745	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2084P0800X	Psychiatry & Neurology - Psychiatry	D0064612 (Maryland)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Kaiser Foundation Health Plan Of The Mid-atlantic States,inc	3779495858	1673

News Archive

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

Merck & Co., Inc., Whitehouse Station, NJ, U.S., announced today plans to phase out the Merck Frosst Centre for Therapeutic Research, located at the head office of its Canadian subsidiary in Kirkland, Québec, by the end of 2010.

FDA acts to prevent distribution of food from rodent-infested facility

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized all FDA-regulated food susceptible to rodent and pest contamination or other filth held at the Durham, North Carolina, warehouse of CFSD, Inc., which does business as Chan's Food Service.

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

On Monday, September 13, U.S. Department of Health and Human Services Secretary Kathleen Sebelius will address approximately 3,000 HIV/AIDS activists and advocates at the United States Conference on AIDS (USCA) in Orlando, Florida, the largest AIDS-related gathering in the country.

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Sinobiopharma, Inc., a fully integrated and highly innovative specialty pharmaceutical company engaged in the research, development, manufacture, and marketing of biopharmaceutical products in China, announced financial results for the fiscal year ended May 31, 2010.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Stephanie Hunt Walsh allows following entities to bill medicare on her behalf.

Entity Name	Kaiser Foundation Health Plan Of The Mid-atlantic States,inc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1043378656 PECOS PAC ID: 3779495858 Enrollment ID: O20080519000558

News Archive

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

FDA acts to prevent distribution of food from rodent-infested facility

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Stephanie Hunt Walsh is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Stephanie Hunt Walsh, MD 6501 N Charles St, Baltimore, MD 21204-6819 Ph: (410) 938-3464	Stephanie Hunt Walsh, MD 301 Hospital Dr, Glen Burnie, MD 21061-5803 Ph: (410) 787-4627

News Archive

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

FDA acts to prevent distribution of food from rodent-infested facility

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Psychiatry & Neurology Doctors in Glen Burnie, MD

Bhavana Sharma, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 Hospital Dr, Glen Burnie, MD 21061 Phone: 410-787-4000
Robyn Epperson, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 30 Greenway St Nw Ste 5, Glen Burnie, MD 21061 Phone: 410-760-9079
Larry Webster Blum, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 203 Hospital Dr Ste 200, Glen Burnie, MD 21061 Phone: 410-553-8160 Fax: 410-553-8159
Steven Roy Daviss, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 301 Hospital Dr, Glen Burnie, MD 21061 Phone: 410-787-4897 Fax: 410-595-1933
Dr. Madhu Sreekanth Jasti, M.D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 203 Hospital Dr Ste 200, Glen Burnie, MD 21061 Phone: 410-553-8160 Fax: 410-553-8159
Dr. Philip Bryan Dvoskin, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1406b Crain Hwy S, Ste 301, Glen Burnie, MD 21061 Phone: 410-760-5588 Fax: 410-760-9727
Dr. Lashire J Diegue, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 Hospital Dr, Glen Burnie, MD 21061 Phone: 410-787-4490

Stephanie Hunt Walsh, MD - Medicare Psychiatry in Glen Burnie, MD

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

FDA acts to prevent distribution of food from rodent-infested facility

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Medicare Reassignments

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

FDA acts to prevent distribution of food from rodent-infested facility

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Merck plans to phase out Merck Frosst Centre for Therapeutic Research by end of 2010

FDA acts to prevent distribution of food from rodent-infested facility

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Psychiatry & Neurology Doctors in Glen Burnie, MD